Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details Narrative)

v3.10.0.1
Basis of Presentation and Significant Accounting Policies (Details Narrative)
3 Months Ended 12 Months Ended
Mar. 31, 2018
USD ($)
Breathalyzers
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Allowances for doubtful accounts for trade receivables $ 596,196   $ 596,196
Bad debt expenses $ 40,859  
Accounts receivable, related parties   470,000
Accrual for estimated sales return  
Deferred revenue 57,725   126,471
Revenue recognition rebates expense 37,544 102,824  
Shipping and handling fee 13,641 18,420  
Cost of net revenue $ 26,944 $ 16,177  
Patents [Member]      
Number of patents | Breathalyzers 10    
Trade Receivable [Member] | Three Customers [Member]      
Concentration risk percentage 76.00%    
Concentration risk, number of customer | Breathalyzers 3    
Fulton Bank of New Jersey [Member]      
Cash $ 631,099   426,927
Bank of America [Member]      
Cash 12,578   7,915
PayPal [Member]      
Cash   $ 3,590
Minimum [Member]      
Normal credit terms extended to customers 30 days    
Maximum [Member]      
Normal credit terms extended to customers 90 days    
Cash, FDIC insured amount $ 250,000    
Maximum [Member] | Patents [Member]      
Finite-lived intangible asset, useful life 17 years